Home

TROY EDWARD WILSON

CIK 1589597 · President and CEO · last filed 2026-08-24

TROY EDWARD WILSON is a President and CEO who has filed 78 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing shows the insider bought $1.2M of KURA on Aug 24, 2026. Across all open-market trades the lifetime net is −$22.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $14.2M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$14.18M

Companies

5

Total Filings

78

Lifetime Open-Market Net

-$22.51M

Filer Profile

Reported Address
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KURA President and CEO 914,650 $13.25 $12.12M -$15.84M 32 2026-08-24
PBYI Director 70,950 $9.55 $677.6K -$913.7K 21 2026-06-15
Avidity Biosciences, Inc. (RNAM) Delisted Director 0 — — $0 1 2026-02-27
RNA Director 97,636 $14.19 $1.39M -$5.75M 10 2025-09-09
Zosano Pharma Corp (ZSAN) Delisted Director 4 $0.56 $2 $0 5 2019-07-18

Recent Filings

78 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-24 KURA Buy (P) +100,000 $1.24M EDGAR
2026-08-17 KURA Buy (P) +100,000 $1.11M EDGAR
2026-06-15 PBYI Mixed +16,200 -$77.7K EDGAR
2026-06-12 PBYI Notice (144) −10,800 -$78.4K EDGAR
2026-03-25 KURA Exer (M) +6,103 $37.5K EDGAR
2026-03-02 — Grant (A) — $0
2026-02-27 Avidity Biosciences, Inc. (RNAM) Delisted Disp (D) −78,802 $0 EDGAR
2026-01-06 KURA Grant (A) — $0 EDGAR
2025-11-14 KURA Grant (A) +182,500 $0 EDGAR
2025-09-29 KURA Notice (144) −36,615 -$331.4K EDGAR
Showing 1–10 of 78
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.